

increasing its utility in surveillance in nonendemic areas. The test could also be useful for confirmation of severe forms of RVF infections in humans since therapy, although experimental and potentially toxic (3), may be available in the near future.

ACKNOWLEDGMENTS

This project was supported by the Swedish National Defense Research Institute (FOA-4) and the U.S. Army.

We thank Joel Dalrymple, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Md., for scientific advice and Erling Norrby, Karolinska Institute, Stockholm, Sweden, for helpful criticism of the manuscript.

LITERATURE CITED

1. Anonymous. Chromatography. Principles and methods. Pharmacia Fine Chemicals AB, Uppsala, Sweden.
2. Barnard, B. J. H., and M. J. Botha. 1977. An inactivated Rift Valley fever vaccine. *J. S. Afr. Vet. Assoc.* 48:45-48.
3. Eddy, G. A., C. J. Peters, G. Meadors, and F. E. Cole, Jr. 1981. Rift Valley Fever vaccine for humans. *Contrib. Epidemiol. Biostat.* 3:124-141.
4. Hildreth, S. W., B. J. Beaty, J. M. Meegan, C. L. Frazier, R. E. Shope. 1982. Detection of La Crosse arbovirus antigen in mosquito pools: application of chromogenic and fluorogenic enzyme immunoassay systems. *J. Clin. Microbiol.* 15:879-884.
5. Johansson, M. E., and J. A. Espmark. 1978. Elimination of inter-species reactive anti-IgG antibody by affinity chromatography. *J. Immunol. Methods* 21:285-293.
6. Laughlin, L. W., J. M. Meegan, L. J. Strausbaugh, D. M. Morens, and R. H. Watten. 1979. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. *Trans. R. Soc. Trop. Med. Hyg.* 73:630-633.
7. Meegan, J. M. 1979. The Rift Valley fever epizootic in Egypt 1977-1978. 1. Description of the epizootic and virological studies. *Trans. R. Soc. Trop. Med. Hyg.* 73:618-623.
8. Murphy, L. C., and B. C. Easterday. 1961. Rift Valley fever: a zoonosis. *Ann. Proc. U.S. Livestock Sanit. Assoc.* 65:397-412.
9. Peters, C. J., and J. M. Meegan. 1981. Rift Valley fever, p. 403-420. *In* G. W. Beran (ed.), *CRC handbook series in zoonoses, section B: viral zoonoses, vol. 1*. CRC Press, Inc., Boca Raton, Fla.
10. Randall, R., C. J. Gibbs, Jr., C. G. Aulisio, L. N. Binn, and V. R. Harrison. 1962. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. *J. Immunol.* 89:660-671.
11. Shope, R. E., J. M. Meegan, C. J. Peters, R. B. Tesh, and A. A. Travassos da Rosa. 1981. Immunologic status of Rift Valley fever virus. *Contrib. Epidemiol. Biostat.* 3:42-52.
12. Swanepoel, R., B. Manning, and J. A. Watt. 1979. Fatal Rift Valley fever of man in Rhodesia. *Cent. Afr. J. Med.* 25:1-8.
13. Thomas, W. J., T. W. O'Neill, D. E. Craig, J. L. DeMelo, and A. N. DeSanctis. 1978. Preparation and use of a stable, inactivated Rift Valley fever antigen. *J. Biol. Stand.* 6:51-58.
14. Van Velden, D. J. J., J. D. Meyer, J. Olivier, J. H. S. Gear, and B. McIntosh. 1977. Rift Valley fever affecting humans in South Africa: a clinicopathological study. *S. Afr. Med. J.* 51:867-871.
15. Voller, A., A. Bartlett, D. E. Bidwell, M. F. Clark, and A. N. Adams. 1976. The detection of viruses by enzyme-linked immunosorbent assay (ELISA). *J. Gen. Virol.* 33:165-167.

DTIC
ELECTE
S OCT 19 1983 **D**
B

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A	21

